Stephen Ansell, MD, PhD, Mayo Clinic, Rochester, MI, highlights the latest developments in lymphoma presented at ASH 2020. More specifically, prof. Ansell underlines novel analysis into different subsets of lymphoma, as well as promising new agents within the categories of antibody-drug conjugates and bispecific antibodies. New agents are being tested in R/R patients with the hope that, in combination with front-line treatment, overall patient outcomes will improve. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
Research funding: Bristol Myers Squibb, Seattle Genetics, ADC Therapeutics, Affimed, Trillium, AI Therapeutics, Regeneron